Ki23057

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2006-2016
01220062016

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
The aim of this study was to clarify the ability of a FGFR-2 inhibitor, Ki23057, to inhibit the VEGFR-2 signaling pathway which… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
Is this relevant?
Review
2014
Review
2014
Fibroblast growth factors (FGFs) are involved in a variety of cellular processes, such as stemness, proliferation, anti-apoptosis… (More)
Is this relevant?
2011
2011
AIM The aim of this study was to clarify the ability of a FGFR2 inhibitor, Ki23057, to enhance the chemosensitivity of drug… (More)
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
2010
2010
Scirrhous gastric carcinoma (SGC) carries the highest mortality because of a frequent metastasis to lymph node (LN). S1, a 5… (More)
Is this relevant?
2010
2010
Evaluation of: Turner N, Pearson A, Sharpe R et al. FGFR1 amplification drives endocrine therapy resistance and is a therapeutic… (More)
Is this relevant?
2010
2010
BACKGROUND/AIM Biliary tract carcinoma (BTC) has extremely poor prognosis because of rapid cancer cell proliferation. The aim of… (More)
Is this relevant?
2009
2009
Background:Vascular endothelial growth factor receptor-3 (VEGFR-3) signalling mediates lymphangiogenesis and lymphatic invasion… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Review
2009
Review
2009
Fibroblast growth factor receptor (FGFR)2 is regulated on the basis of the balance of FGFs, heparan-sulfate proteoglycans, FGFR2… (More)
Is this relevant?
2007
2007
Ki23057 is a new, small synthetic tyrosine kinase inhibitor that blocks autophosphorylation of the VEGF receptor2 (VEGFR2). To… (More)
Is this relevant?
2006
2006
BACKGROUND & AIMS Scirrhous gastric carcinoma carries the highest mortality of all gastric cancers. The poor prognosis is… (More)
Is this relevant?